Leveraging Evolving Data to Inform Treatment in HR-Positive, HER2-Negative Advanced Breast Cancer

In this CME/MOC-certified, on-demand Webcast of a CCO symposium at SABCS 2019, a panel of experts review and discuss evolving strategies for treating HR-positive, HER2-negative advanced breast cancer.
Joyce O'Shaughnessy, MD
Program Director
Hope S. Rugo, MD
Eric P. Winer, MD
Released: January 21, 2020 Expiration: No longer available for credit

Related Content

Short slideset on key trials and approvals for first-generation TRK inhibitors in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 15, 2021

Short expert slideset on when and how to test for NTRK fusions in various solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: October 8, 2021

First-line pembrolizumab + chemotherapy significantly improved OS vs chemotherapy alone in locally recurrent unresectable or metastatic TNBC with PD-L1 CPS ≥10, from ESMO 2021 as reported by Clinical Care Options (CCO)

Released: September 28, 2021

Novel ADC [vic]-trastuzumab duocarmazine significantly prolonged PFS vs physician’s choice treatment in pretreated HER2+ advanced or metastatic breast cancer, presented at ESMO as reported by Clinical Care Options (CCO)

Released: September 28, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Immunomedics, Inc.
Lilly

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue